Journal Article

A retrospective survey of patients who discontinued participation in the JPLSG HLH-2004 clinical trial

Nakazawa, Yozo, Suzuki, Ryoko, Nomura, Keiko, Arakawa, Yuki, Sakamoto, Kenichi, Kozaki, Aiko, Yamasaki, Kai, Suenobu, Souichi, Ono, Rintaro, Doi, Takehiko, Tamura, Akihiro, Ishii, Eiichi, Shioda, Yoko, Miyamura, Takako, Mori, Mari, Mori, Tetsuya, Yanagisawa, Ryu, Miyajima, Yuji, Onuma, Masaei, Kanegane, Hirokazu, Sakaguchi, Kimiyoshi, Yamato, Genki, Okada, Keiko, Hashimoto, Hiroya, Maeda, Naoko

2022

Overview

Although clinical trials have reported an improvement in the prognosis of hemophagocytic lymphohistiocytosis (HLH), current treatment outcomes are unsatisfactory, especially in severe cases. Most clinical trial patients with severe disease discontinue participation due to complications associated with HLH or treatment-related toxicity. A retrospective survey of patients who discontinued participation in the JPLSG HLH-2004 clinical trial was conducted to review the detailed course of these cases to optimize HLH treatment and supportive care. Findings in these patients were compared with those of 45 patients who completed the protocol treatment. The 3 year overall survival rate of patients who completed treatment was 86.7%, versus 50.7% for those who did not complete treatment. Incidence of serious adverse events, such as infections, coagulopathy, and posterior reversible encephalopathy syndrome, during the initial 8 weeks of treatment was much higher in patients who did not complete treatment than in patients who completed treatment. To improve overall outcomes of patients with HLH, it is important to not only optimize HLH-directed therapy but also provide appropriate supportive care.

• Publisher: Springer Nature B.V
• Subject: Clinical trials / Complications / Encephalopathy / Health services / Histiocytosis / Lymphocytosis / Medical prognosis / Patients / Surveys / Survival / Toxicity